Innovative Cannabidiol-based treatments.
Talent is a clinical phase company recently acquired by Kalytera Therapeutics (TSXV: KALY). Talent developed CBD-based drugs for the prevention and treatment of GVHD. The company showed very promising results in four phase 2a trials at Beilinson Medical Center.
GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes.